Adaptations à l'entraînement en résistance et consommation de caféine
Étude des différentes stratégies de supplémentation en caféine sur les adaptations induites par l'entraînement en résistance
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Phase
Phase
- N'est pas applicable
Contacts et emplacements
Coordonnées de l'étude
Coordonnées de l'étude
- Nom: Abdullah Demirli, PhD
- Numéro de téléphone: +90 545 259 22 25
- E-mail: abdullah.demirli@iuc.edu.tr
Sauvegarde des contacts de l'étude
- Nom: Kaan Kaya, PhD
- Numéro de téléphone: +90 546 876 0049
- E-mail: kaan.kaya@yeniyuzyil.edu.tr
Lieux d'étude
-
-
Avcilar
-
Istanbul, Avcilar, Turquie (Türkiye), 34010
- Istanbul University-Cerrahpasa, Faculty of Sport Sciences Performance Laboratory
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
Accepte les volontaires sains
La description
Critères d'inclusion :
- Sexe masculin et âge compris entre 18 et 30 ans
- Aucun antécédent de consommation de caféine ou consommation habituelle très faible (< 50 mg/jour)
- Aucune participation à un programme d'entraînement en résistance régulier au cours des 6 derniers mois
- Indice de masse corporelle (IMC) compris entre 18,5 et 30 kg/m²
- Disponibilité à assister régulièrement à toutes les séances d'entraînement et de tests
- Fourniture d'un consentement éclairé écrit après avoir été pleinement informé sur l'étude
Critères d'exclusion :
- Présence de maladies cardiovasculaires, métaboliques, rénales, hépatiques ou autres maladies chroniques graves
- Troubles psychiatriques diagnostiqués ou intolérance/allergie sévère à la caféine
- Utilisation de médicaments affectant le métabolisme de la caféine ou l'anabolisme musculaire (par exemple, bêta-bloquants, antidépresseurs, stéroïdes anabolisants)
- Blessures musculo-squelettiques empêchant un entraînement en résistance sécuritaire
- Tabagisme ou consommation d'alcool à des niveaux susceptibles d'affecter les résultats de l'étude
- Participation simultanée à une autre étude d'intervention par l'exercice
- Incapacité à tolérer les procédures de scan DXA, de prélèvement sanguin ou d'ingestion de D2O
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Tripler
Nombre de bras
Armes et Interventions
Groupe de participants / BrasGroupe de participants / Bras |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
Expérimental: Strategy 1: Constant Daily Dose
Participants receive caffeine at a constant daily dose of 4 mg/kg/day for 10 weeks.
Supervised resistance training is performed 3 times per week for 10 weeks.
|
Oral caffeine capsule at 4 mg/kg body weight, consumed daily approximately 60 minutes before training sessions (on training days) or at the same time of day (on rest days).
|
|
Expérimental: Strategy 2: Escalating Dose
Participants receive caffeine at a gradually escalating dose, starting at 2 mg/kg/day in week 1 and increasing to 6 mg/kg/day by week 10 (1 mg/kg every 2 weeks).
Supervised resistance training is performed 3 times per week for 10 weeks.
|
• Oral caffeine starting at 2 mg/kg/day and increasing incrementally to reach 6 mg/kg/day by week 10.
|
|
Expérimental: Strategy 3: Training Days Only
Participants receive caffeine at 4 mg/kg only on training days (3 times per week) for 10 weeks.
Supervised resistance training is performed 3 times per week for 10 weeks.
|
Oral caffeine capsule at 4 mg/kg body weight, consumed only on training days approximately 60 minutes before exercise.
|
|
Comparateur placebo: Placebo
Participants receive 250 mg/day cellulose for 10 weeks.
Supervised resistance training is performed 3 times per week for 10 weeks.
|
Oral placebo capsule (250 mg cellulose), consumed daily approximately 60 minutes before training sessions (on training days) or at the same time of day (on rest days).
|
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Change in Lean Body Mass Measured by DXA
Délai: Baseline and post-test (after completing 10 weeks of interventions)
|
Change in total lean body mass measured using dual-energy X-ray absorptiometry (DXA), reported in kilograms.
|
Baseline and post-test (after completing 10 weeks of interventions)
|
|
Change in Fat Mass Measured by DXA
Délai: Baseline and post-test (after completing 10 weeks of interventions)
|
Change in fat mass measured using DXA.
|
Baseline and post-test (after completing 10 weeks of interventions)
|
|
Maximal Strength
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
Measure by one-repetition maximum (1-RM) on a lower body (Smith machine Back Squat) and two upper body (Bench Press machine and Lat Pulldown machine) exercises.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Total Training Volume Load
Délai: During the intervention period (all training sessions).
|
Total training volume load calculated as the sum of lifted load using the formula (kilograms × repetitions × sets) accumulated during each intervention period.
|
During the intervention period (all training sessions).
|
|
Change in Skeletal Muscle Thickness
Délai: Baseline and post-test (after completing 10 weeks of interventions)
|
Change in skeletal muscle thickness measured using B-mode ultrasound, reported in mm.
|
Baseline and post-test (after completing 10 weeks of interventions)
|
Mesures de résultats secondaires
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Muscular endurance
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
It will be measured by a repetitions-to-failure test on the Smith machine back squat using a load corresponding to 60% of the current 1RM.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Neuromuscular function
Délai: Baseline and post-test (after completing 10 weeks of interventions)
|
It will be measured by the countermovement jump (CMJ) test on a force platform.
|
Baseline and post-test (after completing 10 weeks of interventions)
|
|
Resting concentrations of testosterone
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
They will be measured using standard biochemical analyses.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Plasma epinephrine responses to exercise
Délai: During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
They will be measured using standard biochemical analyses.
|
During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
|
Recovery
Délai: Before each of the 30 training sessions during the study.
|
It will be assessed using the validated 0-10 Perceived Recovery Status Scale (0 to 2: very poorly recovered, 3 to 4: poorly recovered, 5 to 6: adequately recovered, 7 to 8: well recovered, and 9 to 10: fully recovered).
|
Before each of the 30 training sessions during the study.
|
|
Adverse Events
Délai: From initiation of the 4-week caffeine abstinence period through completion of the post-intervention assessments, monitored throughout the study (approximately 16 weeks).
|
Adverse events will be assessed using a standardized questionnaire administered throughout the study.
|
From initiation of the 4-week caffeine abstinence period through completion of the post-intervention assessments, monitored throughout the study (approximately 16 weeks).
|
|
Sleep quality
Délai: Baseline and post-test (after completing 10 weeks of interventions).
|
It will be assessed by the Pittsburgh Sleep Quality Index (PSQI).
|
Baseline and post-test (after completing 10 weeks of interventions).
|
|
Rate of perceived exertion
Délai: After each supervised training session, participants were assessed throughout the 10-week intervention period (30 training sessions).
|
Assessed using the Borg Category-Ratio (CR10) Scale, ranging from 0 ("nothing at all") to 10 ("maximal").
Participants will report their perceived exertion after each supervised training session.
|
After each supervised training session, participants were assessed throughout the 10-week intervention period (30 training sessions).
|
|
Resting concentrations of insulin-like growth factor-1 (IGF-1)
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
They will be measured using standard biochemical analyses.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Resting concentrations of cortisol
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
They will be measured using standard biochemical analyses.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Resting concentrations of creatine kinase
Délai: Baseline, and post-test (after completing 10 weeks of interventions)
|
They will be measured using standard biochemical analyses.
|
Baseline, and post-test (after completing 10 weeks of interventions)
|
|
Serum cortisol responses to exercise
Délai: During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
They will be measured using standard biochemical analyses.
|
During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
|
Plasma norepinephrine responses to exercise
Délai: During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
They will be measured using standard biochemical analyses.
|
During the first training session of Week 1 and the final training session of Week 10, at three time points: (1) pre-supplementation, (2) immediately before exercise and (3) immediately after exercise.
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Publications et liens utiles
Publications générales
- Guest NS, VanDusseldorp TA, Nelson MT, Grgic J, Schoenfeld BJ, Jenkins NDM, Arent SM, Antonio J, Stout JR, Trexler ET, Smith-Ryan AE, Goldstein ER, Kalman DS, Campbell BI. International society of sports nutrition position stand: caffeine and exercise performance. J Int Soc Sports Nutr. 2021 Jan 2;18(1):1. doi: 10.1186/s12970-020-00383-4.
- Lovallo WR, Whitsett TL, al'Absi M, Sung BH, Vincent AS, Wilson MF. Caffeine stimulation of cortisol secretion across the waking hours in relation to caffeine intake levels. Psychosom Med. 2005 Sep-Oct;67(5):734-9. doi: 10.1097/01.psy.0000181270.20036.06.
- Matsumura T, Takamura Y, Fukuzawa K, Nakagawa K, Nonoyama S, Tomoo K, Tsukamoto H, Shinohara Y, Iemitsu M, Nagano A, Isaka T, Hashimoto T. Ergogenic Effects of Very Low to Moderate Doses of Caffeine on Vertical Jump Performance. Int J Sport Nutr Exerc Metab. 2023 Jul 26;33(5):275-281. doi: 10.1123/ijsnem.2023-0061. Print 2023 Sep 1.
- Brook MS, Wilkinson DJ, Mitchell WK, Lund JN, Szewczyk NJ, Greenhaff PL, Smith K, Atherton PJ. Skeletal muscle hypertrophy adaptations predominate in the early stages of resistance exercise training, matching deuterium oxide-derived measures of muscle protein synthesis and mechanistic target of rapamycin complex 1 signaling. FASEB J. 2015 Nov;29(11):4485-96. doi: 10.1096/fj.15-273755. Epub 2015 Jul 13.
- Pickering C, Kiely J. Are low doses of caffeine as ergogenic as higher doses? A critical review highlighting the need for comparison with current best practice in caffeine research. Nutrition. 2019 Nov-Dec;67-68:110535. doi: 10.1016/j.nut.2019.06.016. Epub 2019 Jun 26.
- Grgic J, Trexler ET, Lazinica B, Pedisic Z. Effects of caffeine intake on muscle strength and power: a systematic review and meta-analysis. J Int Soc Sports Nutr. 2018 Mar 5;15:11. doi: 10.1186/s12970-018-0216-0. eCollection 2018.
- Grgic J, Grgic I, Pickering C, Schoenfeld BJ, Bishop DJ, Pedisic Z. Wake up and smell the coffee: caffeine supplementation and exercise performance-an umbrella review of 21 published meta-analyses. Br J Sports Med. 2020 Jun;54(11):681-688. doi: 10.1136/bjsports-2018-100278. Epub 2019 Mar 29.
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
- Manifestations neurologiques
- Maladies du système nerveux
- Manifestations neuromusculaires
- Conditions pathologiques, anatomiques
- Atrophie
- Conditions pathologiques, signes et symptômes
- Signes et symptômes
- Hypertrophie
- Atrophie musculaire
- Composés hétérocycliques
- Composés hétérocycliques, 2 anneaux
- Composés hétérocycliques, anneau fusionné
- Alcaloïdes
- Purinones
- Purines
- Xanthines
- Caféine
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- 2026/01-1792
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Délai de partage IPD
Critères d'accès au partage IPD
Type d'informations de prise en charge du partage d'IPD
- PROTOCOLE D'ÉTUDE
- SÈVE
- ANALYTIC_CODE
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .